Brief: Kamada Announces Enrollment Of First Patient Into Its Pivotal Phase 3 Clinical Trial Of Inhaled Aat For The Treatment Of Alpha-1 Antitrypsin Deficiency
16/12/2019 12:05
Dec 16 (Reuters) - Kamada Ltd KMDA.TA :
* KAMADA ANNOUNCES ENROLLMENT OF FIRST PATIENT INTO ITS
PIVOTAL
PHASE 3 INNOVAATE CLINICAL TRIAL OF INHALED AAT FOR THE
TREATMENT OF ALPHA-1 ANTITRYPSIN DEFICIENCY
* KAMADA LTD - EXPECTS TO RECEIVE FURTHER FEEDBACK FROM FDA
RELATED TO ITS HUMAN FACTOR STUDY, WHICH CO COMPLETED IN Q3 2019
Source text for Eikon: ID:nGNX37bGkx
Further company coverage: KMDA.TA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kamada
See all newsBrief: Kamada Updates On Withholding Tax Procedures On Previously Announced Cash Dividend To Shareholders
Brief: Kamada Announces Planned Transition Of Chief Financial Officer
Brief: Kamada Q2 EPS USD 0.16
Brief: Kamada Announces FDA Approval Of Its New In-House Rabies Virus Neutralization Testing Laboratory
Brief: Kamada Q4 EPS USD 0.06